Mylan Inc  

(Public, NASDAQ:MYL)   Watch this stock  
Find more results for Mylan Technologies, Incorporated
+0.20 (0.43%)
Apr 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 44.74 - 47.17
52 week 27.66 - 57.52
Open 46.12
Vol / Avg. 0.00/6.73M
Mkt cap 17.19B
P/E 29.19
Div/yield     -
EPS 1.58
Shares 371.86M
Beta 1.03
Inst. own 90%
May 1, 2014
Q1 2014 Mylan Inc. Earnings Conference Call - 11:00AM EDT - Add to calendar
May 1, 2014
Q1 2014 Mylan Inc. Earnings Release - 9:30AM EDT - Add to calendar
Apr 11, 2014
Mylan Inc. Annual Shareholders Meeting
Mar 11, 2014
Mylan Inc. at Barclays Healthcare Conference
Mar 4, 2014
Mylan Inc. at Cowen Health Care Conference
Feb 27, 2014
Q4 2013 Mylan Inc. Earnings Conference Call
Feb 27, 2014
Q4 2013 Mylan Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 10.01% 9.07%
Operating margin 15.36% 16.80%
EBITD margin - 26.89%
Return on average assets 5.16% 4.61%
Return on average equity 23.48% 19.86%
Employees 20,000 -
CDP Score - -


United States - Map
+1-724-5141800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. The Company's pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan provides products to customers in approximately 140 countries and territories. In December 2013, In December 2013, the Company announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Ltd.

Officers and directors

Robert J. Coury Executive Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rajiv Malik President, Director
Age: 52
Bio & Compensation  - Reuters
Heather M Bresch Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Rodney L. Piatt CPA Vice Chairman of the Board, Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
John D. Sheehan CPA Executive Vice President, Chief Financial Officer, Principal Financial officer
Age: 52
Bio & Compensation  - Reuters
Rakesh Bamzai President - India Commercial and Emerging Markets
Bio & Compensation  - Reuters
Jacek Glinka President - European Business
Age: 50
Bio & Compensation  - Reuters
Anthony Mauro President, North America
Age: 40
Bio & Compensation  - Reuters
Harry A. Korman Chief Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel C. Rizzo Jr., CPA Senior Vice President, Corporate Controller
Age: 50
Bio & Compensation  - Reuters